Heart failure with preserved ejection fraction

New England Journal of Medicine

Volumn 375, Issue 19, 2016, Pages 1868-1877

  Redfield, Margaret M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; NITRIC ACID DERIVATIVE;

AGE; AGED; ATRIAL FIBRILLATION; BODY MASS; CASE REPORT; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; DRUG INDICATION; DYSPNEA; ECHOCARDIOGRAPHY; FATIGUE; FEMALE; FOLLOW UP; GENDER; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART RATE; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPERVOLEMIA; LEG EDEMA; ORTHOPNEA; PATIENT EDUCATION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; REVIEW; SELF CARE; THORAX RADIOGRAPHY; THROMBOEMBOLISM; ALGORITHM; EXERCISE TOLERANCE; HEART STROKE VOLUME; PATHOPHYSIOLOGY;

AGED; ALGORITHMS; DIURETICS; EXERCISE TOLERANCE; FEMALE; HEART FAILURE; HUMANS; STROKE VOLUME;

EID: 84994891162     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcp1511175     Document Type: Review

References (54)

1. Gladden JD, Linke WA, Redfield MM. Heart failure with preserved ejection fraction. Pflugers Arch 2014; 466: 1037-53.
2. Campbell RT, Jhund PS, Castagno D, Hawkins NM, Petrie MC, McMurray JJ. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? J Am Coll Cardiol 2012; 60: 2349-56.
3. Chan MM, Lam CS. How do patients with heart failure with preserved ejection fraction die? Eur J Heart Fail 2013; 15: 604- 13.
4. Lee DS, Gona P, Albano I, et al. A systematic assessment of causes of death after heart failure onset in the community: impact of age at death, time period, and left ventricular systolic dysfunction. Circ Heart Fail 2011; 4: 36-43.
5. Borlaug BA. Mechanisms of exercise intolerance in heart failure with preserved ejection fraction. Circ J 2014; 78: 20-32.
6. Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail 2010; 3: 588-95.
7. Franssen C, Paulus WJ. Normal resting pulmonary artery wedge pressure: A diagnostic trap for heart failure with preserved ejection fraction. Eur J Heart Fail 2015; 17: 132-4.
8. Lam CS, Roger VL, Rodeheffer RJ, et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation 2007; 115: 1982-90.
9. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure -Abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004; 350: 1953-9.
10. Borlaug BA, Lam CS, Roger VL, Rodeheffer RJ, Redfield MM. Contractility and ventricular systolic stiffening in hypertensive heart disease: insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol 2009; 54: 410-8.
11. Dhakal BP, Malhotra R, Murphy RM, et al. Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: The role of abnormal peripheral oxygen extraction. Circ Heart Fail 2015; 8: 286-94.
12. Haykowsky MJ, Tomczak CR, Scott JM, Paterson DI, Kitzman DW. Determinants of exercise intolerance in patients with heart failure and reduced or preserved ejection fraction. J Appl Physiol 2015; 119: 739-44.
13. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013; 62: 263-71.
14. Shah SJ, Kitzman DW, Borlaug BA, et al. Phenotype-specific treatment of heart failure with preserved ejection fraction: A multiorgan roadmap. Circulation 2016; 134: 73-90.
15. Mohammed SF, Hussain S, Mirzoyev SA, Edwards WD, Maleszewski JJ, Redfield MM. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation 2015; 131: 550-9.
16. Mohammed SF, Majure DT, Redfield MM. Zooming in on the microvasculature in heart failure with preserved ejection fraction. Circ Heart Fail 2016; 9(7): e003272.
17. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016; 37: 2129-200.
18. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 128(16): e240-e327.
19. Zile MR, Gottdiener JS, Hetzel SJ, et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation 2011; 124: 2491-501.
20. Borlaug BA, Jaber WA, Ommen SR, Lam CS, Redfield MM, Nishimura RA. Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction. Heart 2011; 97: 964-9.
21. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194-202.
22. Thenappan T, Prins KW, Cogswell R, Shah SJ. Pulmonary hypertension secondary to heart failure with preserved ejection fraction. Can J Cardiol 2015; 31: 430- 9.
23. Chatterjee NA, Steiner J, Lewis GD. It is time to look at heart failure with preserved ejection fraction from the right side. Circulation 2014; 130: 2272-7.
24. Zakeri R, Chamberlain AM, Roger VL, Redfield MM. Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: A communitybased study. Circulation 2013; 128: 1085-93.
25. Iwanaga Y, Nishi I, Furuichi S, et al. B-Type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol 2006; 47: 742-8.
26. Anjan VY, Loftus TM, Burke MA, et al. Prevalence, clinical phenotype, and outcomes associated with normal B-Type natriuretic peptide levels in heart failure with preserved ejection fraction. Am J Cardiol 2012; 110: 870-6.
27. Bishu K, Deswal A, Chen HH, et al. Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. Am Heart J 2012; 164(5): 763-770.e3.
28. Costello-Boerrigter LC, Boerrigter G, Redfield MM, et al. Amino-Terminal pro- B-Type natriuretic peptide and B-Type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 2006; 47: 345-53.
29. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002; 40: 976-82.
30. Richards M, Di Somma S, Mueller C, et al. Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: results from the BACH Study (Biomarkers in ACute Heart Failure). JACC Heart Fail 2013; 1: 192-9.
31. Hwang SJ, Melenovsky V, Borlaug BA. Implications of coronary artery disease in heart failure with preserved ejection fraction. J Am Coll Cardiol 2014; 63: 2817-27.
32. Pichard AD, Diaz R, Marchant E, Casanegra P. Large V waves in the pulmonary capillary wedge pressure tracing without mitral regurgitation: The influence of the pressure/volume relationship on the V wave size. Clin Cardiol 1983; 6: 534-41.
33. Rossi A, Gheorghiade M, Triposkiadis F, Solomon SD, Pieske B, Butler J. Left atrium in heart failure with preserved ejection fraction: structure, function, and significance. Circ Heart Fail 2014; 7: 1042-9.
34. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016; 133: 2404-12.
35. Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-Type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015; 36: 2585-94.
36. Anderson JL, Halperin JL, Albert NM, et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127: 1425-43.
37. Shah RV, Desai AS, Givertz MM. The effect of renin-Angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: A systematic review and meta-Analysis. J Card Fail 2010; 16: 260-7.
38. Pfeffer MA, Pitt B, McKinlay SM. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 371: 181-2.
39. Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 2015; 131: 34-42.
40. Conraads VM, Metra M, Kamp O, et al. Effects of the long-Term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail 2012; 14: 219-25.
41. Liu F, Chen Y, Feng X, Teng Z, Yuan Y, Bin J. Effects of beta-blockers on heart failure with preserved ejection fraction: A meta-Analysis. Plos One 2014; 9(3): e90555.
42. van Veldhuisen DJ, Cohen-Solal A, Bohm M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 2009; 53: 2150-8.
43. Yamamoto K, Origasa H, Hori M. Effects of carvedilol on heart failure with preserved ejection fraction: The Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 2013; 15: 110-8.
44. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507- 20.
45. Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373: 2103-16.
46. Alehagen U, Benson L, Edner M, Dahlstrom U, Lund LH. Association between use of statins and mortality in patients with heart failure and ejection fraction of ≥50. Circ Heart Fail 2015; 8: 862-70.
47. Ohman EM. Chronic stable angina. N Engl J Med 2016; 374: 1167-76.
48. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130(23): e199-e267.
49. Kitzman DW, Brubaker P, Morgan T, et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: A randomized clinical trial. JAMA 2016; 315: 36-46.
50. Redfield MM, Anstrom KJ, Levine JA, et al. Isosorbide mononitrate in heart failure with preserved ejection fraction. N Engl J Med 2015; 373: 2314-24.
51. Pandey A, Parashar A, Kumbhani DJ, et al. Exercise training in patients with heart failure and preserved ejection fraction: meta-Analysis of randomized control trials. Circ Heart Fail 2015; 8: 33-40.
52. Adamson PB, Abraham WT, Bourge RC, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail 2014; 7: 935-44.
53. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 doubleblind randomised controlled trial. Lancet 2012; 380: 1387-95.
54. Nanayakkara S, Kaye DM. Management of heart failure with preserved ejection fraction: A review. Clin Ther 2015; 37: 2186-98.